postmenopausal osteoporosis

Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis.

Ipriflavone in the treatment of postmenopausal osteoporosis: A randomized controlled trial.

Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.

Inhibitors of IL-6 (including estrogen) are used to treat postmenopausal osteoporosis.

The form of osteoporosis most common in women after menopause is referred to as primary type 1 or postmenopausal osteoporosis.

Pfizer are seeking approval for bazedoxifene in the prevention and treatment of postmenopausal osteoporosis.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis.

Drugs for postmenopausal osteoporosis (2008).

Meta-analyses of therapies for postmenopausal osteoporosis.

Lactose and calcium absorption in postmenopausal osteoporosis.

Vitamin K nutrition and postmenopausal osteoporosis.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

Teriparatide ( a recombinant parathyroid hormone ) has been shown to be effective in treatment of women with postmenopausal osteoporosis.

"In contrast to the pessimistic view held by many only a few years ago, it is now clear that postmenopausal osteoporosis can be treated effectively," he said.

Postmenopausal osteoporosis.

Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial.

Fluoride for treating postmenopausal osteoporosis.

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

The anti-resorbing agent 17β-estradiol is especially noteworthy because of the association of its decline at menopause with the development of postmenopausal osteoporosis.

Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club.

In an 18 month double-blind, placebo controlled study, the effects of Preotact on the fracture incidence in 2532 women with postmenopausal osteoporosis was studied.

Raloxifene is a second-generation SERM approved for prophylaxis against postmenopausal osteoporosis.

Prolia (denosumab) (for postmenopausal osteoporosis)